Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorAndretta, Elena
dc.contributor.authorCarton García, Fernando
dc.contributor.authorMartinez Barriocanal, Agueda
dc.contributor.authorGuimaraes De Marcondes, Priscila
dc.contributor.authorJimenez Flores, Lizbeth Minerva
dc.contributor.authorMacaya Erro, Irati
dc.contributor.authorBazzocco, Sarah
dc.contributor.authorBilic Zimmermann, Josipa
dc.contributor.authorGonçalves Rodrigues, Paulo Andre
dc.contributor.authorNieto Raya, Rocio
dc.contributor.authorRamon y Cajal Agüeras, Santiago
dc.contributor.authorSchwartz Navarro, Simon
dc.contributor.authorDopeso Gonzalez, J Higinio
dc.contributor.authorArango Corro, Diego
dc.contributor.authorLandolfi, Stefania
dc.date.accessioned2019-03-14T06:58:35Z
dc.date.available2019-03-14T06:58:35Z
dc.date.issued2017-02-07
dc.identifier.citationAndretta E, Cartón-García F, Martínez-Barriocanal Á, de Marcondes PG, Jimenez-Flores LM, Macaya I, et al. Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer. Sci Rep. 2017;7(1):41576.
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/11351/3841
dc.descriptionTyrosine kinase; EPHA3; Colorectal cancer
dc.description.abstractEPH signaling deregulation has been shown to be important for colorectal carcinogenesis and genome-wide sequencing efforts have identified EPHA3 as one of the most frequently mutated genes in these tumors. However, the role of EPHA3 in colorectal cancer has not been thoroughly investigated. We show here that ectopic expression of wild type EPHA3 in colon cancer cells did not affect their growth, motility/invasion or metastatic potential in vivo. Moreover, overexpression of mutant EPHA3 or deletion of the endogenous mutant EPHA3 in colon cancer cells did not affect their growth or motility. EPHA3 inactivation in mice did not initiate the tumorigenic process in their intestine, and had no effects on tumor size/multiplicity after tumor initiation either genetically or pharmacologically. In addition, immunohistochemical analysis of EPHA3 tumor levels did not reveal associations with survival or clinicopathological features of colorectal cancer patients. In conclusion, we show that EPHA3 does not play a major role in colorectal tumorigenesis. These results significantly contribute to our understanding of the role of EPH signaling during colorectal carcinogenesis, and highlighting the need for detailed functional studies to confirm the relevance of putative cancer driver genes identified in sequencing efforts of the cancer genome.
dc.language.isoeng
dc.publisherNature Research
dc.relation.ispartofseriesScientific Reports;7
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCòlon - Càncer
dc.subjectMucosa intestinal
dc.subjectQuinases
dc.subject.meshColorectal Neoplasms
dc.subject.mesh/genetics
dc.subject.meshIntestinal Mucosa
dc.subject.mesh/metabolism
dc.subject.meshReceptor Protein-Tyrosine Kinases
dc.titleInvestigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/srep41576
dc.subject.decsneoplasias colorrectales
dc.subject.decs/genética
dc.subject.decsmucosa intestinal
dc.subject.decs/metabolismo
dc.subject.decsreceptores proteína-tirosina cinasas
dc.relation.publishversionhttps://www.nature.com/articles/srep41576
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Andretta E, Cartón-García F, Martínez-Barriocanal Á, de Marcondes PG, Jimenez-Flores LM, Macaya I, Bazzocco S, Bilic J, Rodrigues P, Nieto R] Grup de Recerca Biomèdica en Tumors Digestius, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Landolfi S, Ramon Y Cajal S] Servei de Patologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Schwartz S] Grup de Direccionament i Alliberament Farmacològic, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain. [Dopeso H, Arango D] Grup de Recerca Biomèdica en Tumors Digestius, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain.
dc.identifier.pmid28169277
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record